• 1. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 2. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 3. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 4. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 5. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007

Research Briefing on 1-[4-(Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine hydrochloride (CAS: 2724208-31-3)

The compound 1-[4-(Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine hydrochloride (CAS: 2724208-31-3) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. This boronic acid derivative is particularly notable for its role as a key intermediate in the synthesis of bioactive molecules, especially those targeting proteases and other enzymes involved in disease pathways. Recent studies have highlighted its utility in the development of novel therapeutics for conditions such as cancer, inflammatory diseases, and infectious diseases.

One of the most promising aspects of this compound is its incorporation of a boronic ester moiety, which enhances its reactivity and selectivity in binding to biological targets. The tetramethyl-1,3,2-dioxaborolane group is a protected form of boronic acid, which improves the compound's stability and solubility, making it more amenable for use in biological assays and drug formulations. The piperidine ring further contributes to its pharmacological properties by influencing its pharmacokinetic profile and target affinity.

Recent research has focused on optimizing the synthesis of 1-[4-(Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine hydrochloride to improve yield and purity. Advanced techniques such as microwave-assisted synthesis and flow chemistry have been employed to achieve these goals. Additionally, computational modeling and structure-activity relationship (SAR) studies have provided insights into how modifications to the piperidine or boronic ester groups can enhance the compound's efficacy and reduce potential off-target effects.

In preclinical studies, this compound has demonstrated promising results as a protease inhibitor, particularly in the context of cancer therapy. For instance, it has shown inhibitory activity against proteases that are overexpressed in certain tumors, thereby reducing tumor growth and metastasis. Furthermore, its ability to cross the blood-brain barrier makes it a candidate for treating neurological disorders where protease dysregulation is implicated.

Despite these advancements, challenges remain in the clinical translation of 1-[4-(Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine hydrochloride. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through further research. Collaborative efforts between academic institutions and pharmaceutical companies are underway to overcome these hurdles and accelerate the development of this compound into a viable therapeutic agent.

In conclusion, 1-[4-(Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine hydrochloride represents a versatile and promising scaffold in medicinal chemistry. Its unique chemical properties and biological activities make it a valuable tool for drug discovery, and ongoing research is expected to unlock its full potential in treating a range of diseases. Future studies should focus on refining its synthesis, elucidating its mechanism of action, and evaluating its safety and efficacy in clinical settings.

• 1206641-17-9(N,N-Dipropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline)
• 2368222-27-7(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl-2,3,5,6-d4)piperidine-2,2,3,3,4,4,5,5,6,6-d10)
• 852227-90-8(1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrrolidine)
• 2368222-21-1(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidine-2,2,3,3,4,4,5,5-d8)
• 2368222-22-2(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl-2,3,5,6-d4)pyrrolidine-2,2,3,3,4,4,5,5-d8)
• 2368222-26-6(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine-2,2,3,3,4,4,5,5,6,6-d10)
• 1398331-33-3(1-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidin-3-ol)
• 1704095-28-2(4-Methyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine)
• 852227-96-4(1-4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenylpiperidine)
• 852227-97-5(1-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine)